P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses ; volume:6 ; number:3 ; day:22 ; month:10 ; year:2009 ; pages:1 ; date:10.2009
Retrovirology ; 6, Heft 3 (22.10.2009), 1, 10.2009
- Creator
-
Wild, J.
- Contributor
-
Köstler, J.
Bredl, S.
Böckl, K.
Kindsmüller, K.
Wagner, R.
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-6-S3-P352
- URN
-
urn:nbn:de:1111-2016080711472
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wild, J.
- Köstler, J.
- Bredl, S.
- Böckl, K.
- Kindsmüller, K.
- Wagner, R.
- SpringerLink (Online service)
Other Objects (12)
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
P19-36. Preclinical study of CombiHIVvac vaccine
P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
P19-30. GTU® as beneficial HIV DNA vaccine vector system
P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
P19-28. The V3 region of HIV-1: from NMR to vaccine design
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform
P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
P19-36. Preclinical study of CombiHIVvac vaccine
P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
P19-30. GTU® as beneficial HIV DNA vaccine vector system
P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
P19-28. The V3 region of HIV-1: from NMR to vaccine design
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform
P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
P19-36. Preclinical study of CombiHIVvac vaccine
P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
P19-30. GTU® as beneficial HIV DNA vaccine vector system
P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
P19-28. The V3 region of HIV-1: from NMR to vaccine design
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform